fbpx

Monte Rosa Therapeutics Inc

GLUE

$10.22

Closing

▼-1.35%

1D

▲80.88%

YTD

GLUE

BBG00X2VGZR2

Exchange

Sector

Market cap

$632.80M

Volume

306,475

Check if the stock is halal

Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $6.99/month

Market cap

$632.80M

Analysts' Rating

BUY

Price Target (Mean)

15.83

Total Analysts

8

P/E

Operating Margin

-695.25%

Beta

1.37

Revenue Growth

0.00%

52 week high

$12.39

52 week low

$2.95

Div. Yield

%

EPS Growth

-18.87

Company Profile

Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs) for patients living with serious diseases in the areas of oncology and autoimmune, and more. MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a degradation platform, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.